杜塔斯特作为一种治疗方法来支持减少饮酒:一个随机的安慰剂控制试验
Journal of addiction medicine
|November 10, 2025
概括
杜塔斯特有效地减少了因酒精使用障碍而寻求治疗的男性的大量饮酒日和每周饮酒量. 药物耐受性很好,尽管在这个试验中的女性中,它的疗效并不显著.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
背景情况:
- 神经活性类固醇会影响酒精的作用.
- 杜塔胺抑制了5-α减少酶,影响了神经活性类固醇的产生.
- 以前的试验表明,杜塔斯特在减少男性酒精消费方面的潜力.
研究的目的:
- 评估杜塔斯特在减少酒精消费方面的耐受性和有效性.
- 评估杜塔斯特对男性和女性重度饮酒的影响.
主要方法:
- 旨在减少饮酒量的167名重饮者被随机分配给每天服用安慰剂或1毫克杜塔的12周时间.
- 在整个研究过程中,对参与者的饮酒模式进行了监测.
主要成果:
- 参与者可以很好地容忍杜塔斯特.
- 与安慰剂相比,dutasteride显著减少了大量饮酒的日子和每周的饮料.
- 随着杜塔斯特的使用,男性的饮酒量显著减少,而女性则没有,这可能是由于安慰剂反应很高.
结论:
- 每天服用1毫克的杜塔斯特对于减少有酒精使用障碍的男性重度饮酒是有效的.
- 这些发现证实了先前关于杜塔斯特在男性中的疗效的研究.
- 可能需要进一步的研究来探索杜塔斯特在女性中的疗效.
更多相关视频
07:31Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
8.5K
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
3.9K
相关概念视频
Blinding
2.9K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.9K
Drugs for Treatment of Diarrhea-Predominant IBS
1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
764
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
764
